Recruiting
Meningococcal immunisation
RecruitingStudy on Immune Response Differences to Meningococcal Group B Vaccine in Healthy Transgender and Cisgender Adults Aged 18-40
Registered drugNo placebo
Study on Immune Response Differences to Meningococcal Group B Vaccine in Healthy Transgender and Cisgender Adults Aged 18-40
Registered drugNo placebo
- Disease:Meningococcal immunisation
- Substances:Outer Membrane Vesicles (Omv) From Neisseria Meningitidis Group B Strain Nz98/254 Measured As Amount Of Total Protein Containing The Pora P1.4 Adsorbed On Aluminium HydroxideRecombinant Neisseria Meningitidis Group B Fhbp Fusion Protein Produced In E. Coli Cells By Recombinant Dna Technology Adsorbed On Aluminium Hydroxide+2
Countries:
Belgium
Belgium- Participants:18–64 years · Healthy volunteers
- Substances:Outer Membrane Vesicles (Omv) From Neisseria Meningitidis Group B Strain Nz98/254 Measured As Amount Of Total Protein Containing The Pora P1.4 Adsorbed On Aluminium Hydroxide
- Sponsor:Universiteit Gent
